Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31266962.
- Also identified by DOI 10.1038/s41467-019-10954-y and PMC identifier 6606648.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Oncogenic mutations in KRAS or BRAF are frequent in colorectal cancer and activate the ERK kinase. Here, we find graded ERK phosphorylation correlating with cell differentiation in patient-derived colorectal cancer organoids with and without KRAS mutations. Using reporters, single cell transcriptomics and mass cytometry, we observe cell type-specific phosphorylation of ERK in response to transgenic KRAS<sup>G12V</sup> in mouse intestinal organoids, while transgenic BRAF<sup>V600E</sup> activates ERK in all cells. Quantitative network modelling from perturbation data reveals that activation of ERK is shaped by cell type-specific MEK to ERK feed forward and negative feedback signalling. We identify dual-specificity phosphatases as candidate modulators of ERK in the intestine. Furthermore, we find that oncogenic KRAS, together with β-Catenin, favours expansion of crypt cells with high ERK activity. Our experiments highlight key differences between oncogenic BRAF and KRAS in colorectal cancer and find unexpected heterogeneity in a signalling pathway with fundamental relevance for cancer therapy.
Medical subject headings
- Colonic Neoplasms
- Intestinal Mucosa
- Mitogen-Activated Protein Kinase Kinases
- Proto-Oncogene Proteins p21(ras)